Your browser is no longer supported. Please, upgrade your browser.
ImmunityBio, Inc.
Index- P/E- EPS (ttm)-0.96 Insider Own0.90% Shs Outstand391.85M Perf Week27.91%
Market Cap3.15B Forward P/E- EPS next Y-0.88 Insider Trans-1.85% Shs Float80.91M Perf Month-0.51%
Income-287.70M PEG- EPS next Q-0.24 Inst Own8.30% Short Float11.25% Perf Quarter-31.55%
Sales0.60M P/S5242.41 EPS this Y-27.80% Inst Trans14.69% Short Ratio8.26 Perf Half Y-55.31%
Book/sh-0.48 P/B- EPS next Y- ROA-129.10% Target Price25.00 Perf Year-18.68%
Cash/sh0.20 P/C39.17 EPS next 5Y-1.70% ROE176.50% 52W Range5.78 - 45.42 Perf YTD-41.56%
Dividend- P/FCF- EPS past 5Y23.10% ROI-60.70% 52W High-84.79% Beta1.85
Dividend %- Quick Ratio1.40 Sales past 5Y-14.00% Gross Margin- 52W Low19.55% ATR0.55
Employees538 Current Ratio1.40 Sales Q/Q-50.00% Oper. Margin- RSI (14)43.85 Volatility11.48% 7.49%
OptionableYes Debt/Eq- EPS Q/Q-30.10% Profit Margin- Rel Volume2.19 Prev Close7.79
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume1.10M Price6.91
Recom2.00 SMA20-6.47% SMA50-18.84% SMA200-55.12% Volume1,377,038 Change-11.30%
Nov-18-21 09:00AM  
Nov-08-21 05:14PM  
Nov-04-21 09:00AM  
Oct-19-21 09:00AM  
Oct-13-21 09:00AM  
Oct-04-21 08:30AM  
Sep-13-21 08:30AM  
Sep-07-21 08:30AM  
Sep-01-21 09:00AM  
Aug-16-21 09:00AM  
Jul-27-21 09:00AM  
Jul-14-21 09:00AM  
Jun-28-21 09:00AM  
Jun-23-21 04:05PM  
Jun-15-21 07:00AM  
Jun-10-21 09:00AM  
May-25-21 09:00AM  
May-24-21 09:00AM  
May-20-21 09:00AM  
May-17-21 09:00AM  
May-04-21 09:00AM  
Apr-29-21 09:00AM  
Apr-22-21 09:00AM  
Apr-08-21 09:00AM  
Apr-01-21 09:00AM  
Mar-29-21 09:00AM  
Mar-26-21 03:04PM  
Mar-22-21 09:00AM  
Mar-15-21 09:00AM  
Mar-11-21 09:00AM  
Mar-10-21 09:00AM  
ImmunityBio, Inc., a clinical-stage immunotherapy company, develops cell and immune therapies to treat cancers and infectious diseases. The company develops Anktiva (N-803), an IL-15 superagonist and PD-L1 that activates natural killer and T effector cells in combination with chemo and trodelvy to treat cancers, such as merkel cell carcinoma, advanced pancreatic cancer, and advanced triple negative breast cancer; and an albumin-linked formulation of doxorubicin (Aldoxorubicin) to treat breast cancer, hodgkin lymphoma, SCLC, sarcoma, and glioblastoma. It also develops a memory T-cell cancer vaccine to deliver tumor-associated antigens and neoepitopes; and a human adenovirus 5 COVID-19 vaccine. The company was founded in 2014 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Adcock RichardCEO & PresidentOct 08Buy8.811,93016,9951,930Oct 08 08:31 PM
Sachs David C.Chief Financial OfficerSep 09Option Exercise0.007,598026,458Sep 13 08:34 PM
Adcock RichardChief Executive OfficerSep 09Option Exercise0.008,620090,449Sep 13 08:32 PM
Cohen CherylDirectorAug 23Sale10.1214,801149,795200,617Aug 24 06:07 PM
Cohen CherylDirectorAug 20Sale10.009,97699,808215,418Aug 24 06:07 PM
Cohen CherylDirectorAug 18Sale10.032,13321,389225,394Aug 19 08:42 PM
Cohen CherylDirectorAug 17Sale10.1243,398439,361227,527Aug 19 08:42 PM
Simon Barry J.DirectorMay 25Sale16.1888,7871,436,8223,102,507May 25 08:00 PM
Simon Barry J.DirectorMay 24Sale16.0221,223340,0713,191,294May 25 08:00 PM
Simon Barry J.DirectorMay 21Sale16.0914,990241,1643,212,517May 25 08:00 PM
Simon Barry J.DirectorMay 05Option Exercise1.7556,96799,9433,227,507May 07 04:09 PM